Moderate ResearchLongevitySexual Health

Testagen

KEDG

KEDG Tetrapeptide | Testicular Bioregulator

Half-life

Not established

Chain length

4 amino acids

Reference frequency

Daily for 10-20 days, then break

Research overview

DoseGear research brief

Testagen is a Khavinson bioregulator tetrapeptide (KEDG) originally isolated from testicular tissue extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it promotes testosterone biosynthesis by stimulating Leydig cell activity and improving cellular metabolism in testicular tissue. Research shows it helps restore normal communication within the hypothalamic-pituitary-gonadal (HPG) axis, governing testosterone production and spermatogenesis.

Mechanism of action

Testagen works through epigenetic regulation, crossing both cell and nuclear membranes to interact directly with DNA of target tissues. It penetrates into cytoplasm, nucleus, and nucleolus of cells, interacting with various cellular components including DNA and RNA. The peptide can discriminate between different nucleotide sequences and recognize cytosine methylation status. It interacts with the anterior pituitary gland and endocrine pathways involved in testosterone and TSH synthesis, restoring HPG axis communication.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

KEDG tetrapeptide attributed to Khavinson testicular-tissue research.

What it is researched for

Experimental gonadal and endocrine regulation through proposed steroidogenic gene-regulation effects.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Chart reference	100 mcg	Daily · See source guide	Injectable · 20 mg lyophilized vial + 3 mL BAC Water

Reference cycle

10-20 day cycles (typical bioregulator protocol)

Reference storage

Capsules: room temperature; Reconstituted: 2-8°C

Safety context

Reported side effects

Generally well-tolerated
Minimal side effects reported

Contraindications & cautions

Hormone-sensitive cancers (consult oncologist)
Known hypersensitivity
Female use not established

Scientific references

01
Testagen Bioregulator Research on Testosterone and Leydig Cells
Scientific citationTestagen Bioregulator Research on Testosterone and Leydig Cells. Advances in Gerontology (2018).
02
Short Peptides and HPG Axis Function
Scientific citationShort Peptides and HPG Axis Function. Bulletin of Experimental Biology and Medicine (2016).
03
Epigenetic Effects of Short Peptides
Scientific citationEpigenetic Effects of Short Peptides. Neuroendocrinology Letters (2014).
04
Khavinson Peptide Bioregulators
Scientific citationKhavinson Peptide Bioregulators. Advances in Gerontology (2020).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity